Ivor Royston

Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA.

TargeGen, Inc. manufactures vascular biopharmaceutical products. The company was founded by David A. Cheresh and Peter G. Ulrich in 2001 and is headquartered in San Diego, CA.

MyMedicalRecords, Inc. provides web-based personal health record and vital document storage solutions. It includes documents, images, and voice mail messages to be transmitted in and out of the MMR system using a variety of methods like fax, file upload, and email. The company was founded by Russel Armstrong and Robert H. Lorsch in 2005 and is headquartered in Los Angeles, CA.

IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA.

Avalon Pharmaceuticals, Inc. was a biopharmaceutical company focused on the discovery, development and commercialization of cancer therapeutics. The company was founded in November 1999 and headquartered in Germantown, MD.

Forward Ventures Services LLC (Forward Ventures ) is a venture capital firm founded in 1990 by Standish M. Fleming and Ivor Royston. The firm is headquartered in San Diego, California.

Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD.

San Diego Cancer Center is a leading health system that offers primary and specialty care with state-of-the-art facilities. The private company is based in Vista, CA. The company has emergency rooms in various locations, including Chula Vista, and offer medical interpreters for patients with limited English proficiency or communication difficulties. The company also has urgent care centers in Rancho Bernardo and Oceanside, and offer a wide range of medical, surgical, and support services throughout San Diego. The company was founded by Mark J. Adler.

Part of Sanford Burnham Prebys Medical Discovery Institute, Sidney Kimmel Cancer Center provides medical research services. The company is based in San Diego, CA. Sidney Kimmel Cancer Center was acquired by Sanford Burnham Prebys Medical Discovery Institute on June 23, 2009 for $25 million.

HemaQuest Pharmaceuticals, Inc. develops small molecule therapeutics. Its products include hydroxyurea, a therapeutic agent for the treatment of underlying pathology of sickle cell anemia and for the treatments of beta thalassemia, sickle cell anemia, neutropenia, and various hematological disorders. The company was founded by Ronald J. Berenson, Douglas V. Faller, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos and Robert Williams in October 2007 and is headquartered in San Diego, CA.

CONNECT creates and scales companies in the technology and life sciences sectors. It creates an environment in which entrepreneurs and C-suite executives have access to the people, capital, and technology resources. The organization was founded in 1985 and is headquartered in San Diego, CA.

Altair is a privately owned company that was spun out of ISIS Pharmaceuticals in October 2007 with the objective of applying ISIS’s proprietary second generation (2’-MOE Gapmer) antisense oligoneucleotide technology to the field of inhaled therapeutics. Through its collaboration with ISIS Altair has access to both near term clinical stage opportunities, as well as early stage development projects. Altair's first compound AIR645 is currently in phase I clinical trials. This first in class compound posses unique anti-inflammatory activities appropriate for multiple therapeutic applications, including asthma, rhinitis and COPD. Additionally, the characteristics of the 2'-MOE Gapmer chemistry provides for the possibility of administration of AIR645 as an inhaled therapeutic delivered once weekly. Altair is also planning on developing a future pipeline of other best-in-class molecules for respiratory targets by exploiting the advantages of its propriety 2nd generation antisense oligonucleotide chemistry.

La Jolla Playhouse, Inc. provides educational opportunities for children, teens, and adults interested in theatre arts. The company was founded by Gregory Peck, Dorothy McGuire, and Mel Ferrer in 1947 and is headquartered in La Jolla, CA.

MMRGlobal, Inc. provides secure and web-based storage solutions. The company serves consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. Its product portfolio comprises of MyMedicalRecords, MyEsafeDepositBox, MMRPatientView and MMRPro. The company was founded in 2000 and is headquartered in Los Angeles, CA.

Part of IDEC Corp., the company is a manufacturer and distributor of control equipment and related products. The company is based in Sunnyvale, CA and was founded by Ivor Royston. Toshiyuki Funaki has been the CEO of the company since 1975.

The Life Sciences Foundation engaged in education and biotechnology information dissemination. It collected and organized historical information to educate future innovators, to engage the general public, and to provide lay audiences with an understanding of life sciences and biotechnology. The company was founded by G. Steven Burrill, Dennis Gillings, John Lechleiter, Henri Termeer, and Arnold Thackray in 2010 and was headquartered in San Francisco, CA.

Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA.